Table 2.
Clinical outcome variables (adjusted using SuperLearner)
| IGAM group (n = 146) | Controls (n = 170) | HRadjusted (95%-CI) | p value | |
|---|---|---|---|---|
| Primary outcome | ||||
| 30-day mortality, n (%) | 42 (28.8%) | 54 (31.8%) | 0.83 (0.55 to 1.25) | 0.374 |
| Secondary outcomes, median [IQR] | ||||
| Organ support-free days at 30 days | 0 [-1; 10] | 0 [-1; 22] | 1.03 (0.81 to 1.32) | 0.817 |
| Ventilator-free days at 30 days | 0 [-1; 16] | 1 [-1; 22] | 1.10 (0.87 to 1.38) | 0.443 |
| Vasopressor-free days at 30 days | 0 [-1; 21.5] | 1.5 [-1; 29] | 1.00 (0.79 to 1.26) | 0.994 |
| Dialysis-free days at 30 days | 9 [-1; 19] | 8.5 [-1; 19] | 1.03 (0.79 to 1.34) | 0.828 |
| ICU length of stay | 24 [14; 40] | 20 [10; 34] | n/a | 0.040 |
| ICU-free days at 30 days | 0 [-1; 4] | 0 [-1; 6] | n/a | 0.943 |
| Hospital length of stay | 33 [20; 50] | 25.5 [16; 42] | n/a | 0.010 |
IGAM IgM-enriched intravenous immunoglobulins; ICU intensive care unit